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Abstract
Parkinson's disease is the most common neurodegenerative movement disorder and affects about
2% of the population over the age of 60 years. In 2004, mutations in the LRRK2 gene were first
described and turned out to be the most frequent genetic cause of familial and sporadic Parkinson's
disease and may account for up to 40% of patients in distinct populations. Based on these findings,
Latourelle and colleagues show that the penetrance of the most common LRRK2 mutation is higher
in patients with familial compared with sporadic Parkinson's disease and identified a substantial
number of affected relatives of mutation carriers not presenting with a LRRK2 mutation themselves.
This commentary discusses the role of genetic and/or environmental susceptibility factors
modulating the expressivity of the disease trait, how these factors may contribute to the
phenomenon of phenocopies in genetically defined Parkinson's disease pedigrees, and how the
findings of Latourelle and colleagues, published this month in BMC Medicine, relate to current
concepts of genetic counselling.
Parkinson's disease (PD) is the most common neurode-
generative movement disorder, and has been regarded as
a prototypic non-genetic disorder for a long time. First
insight into the genetic contribution to the typical Parkin-
sonian phenotype came from large families with classical
Mendelian inheritance of the disease trait. The discovery
of disease-causing mutations in the alpha-synuclein gene
for autosomal dominant forms and in the Parkin, PINK1
and  DJ-1  gene for autosomal recessive forms of PD
allowed a first insight into the molecular mechanisms that
mediate neurodegeneration in PD. Heterozygous muta-
tions in the alpha-synuclein gene and homozygous muta-
tions in the Parkin, PINK1 and DJ-1 gene show, in general,
full penetrance and account for less than 1% of all PD
cases [1]. Thus, due to the small proportion of PD patients
that carried mutations in the respective genes, genetic test-
ing and counselling of presymptomatic mutation carriers
was not relevant and common recommendations limited
molecular testing to symptomatic individuals. These
premises have now changed due to the identification and
characterization of mutations in the LRRK2 gene in PD
[2,3].
Mutations in the LRRK2 gene encoding the leucine-rich,
repeat kinase 2 protein are the most frequent genetic cause
of PD known to date. Clinicogenetic studies clearly
showed that the majority of all LRRK2 mutation carriers
present with symptoms indistinguishable from idiopathic
PD [4-7]. To date, more than 50 variants are known, but
only about 10% have been proven pathogenic and
account for approximately 2% of sporadic and 10% of
familial PD cases [4,8,9]. Initially identified in large fam-
ilies with autosomal dominant inheritance of PD, it
turned out that mutations in the LRRK2 gene were also
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found in patients with the sporadic form of the disease
(without positive family history). Among these muta-
tions, a glycine to serine exchange in position 2019 of the
peptide sequence (G2019S) is the most frequent world-
wide with frequencies ranging from 1% in European to
40% in North African sporadic PD patients [10]. Increas-
ing evidence for incomplete penetrance of LRRK2 muta-
tions presented a major challenge for diagnostic testing
and genetic counselling and highlighted the unmet need
of validated estimates of population frequency and
expressivity of the disease trait.
Focusing on the most common exemplary G2019S muta-
tion, this month in BMC Medicine, Latourelle and col-
leagues addressed the problem of ascertainment bias that
contributed to a wide range of penetrance estimates in
previous studies on LRRK2 with lifetime penetrance rang-
ing from 35% to 100% [5,11,12]. Indeed recruitment of
patients for genetic studies from specialized institutions
and/or inclusion of volunteer patients are suspected to
overestimate mutation penetrance due to over-representa-
tion of families with multiple affected individuals based
on an increased awareness of the disease [13]. Latourelle
and colleagues used an elegant statistical approach to cor-
rect for inflated penetrance in their family-based study by
using affected sib-pairs as a selection criterion and
assessed penetrance for the parents irrespective of their
disease status. Sufficiently powered population-based
studies are still not available and are difficult to perform
due to economical and ethical issues. Therefore, the
present study represents a first step to overcoming esti-
mates based on studies that were critically exposed to
selection bias towards multiplex families, leading to over-
estimation of penetrance.
Latourelle and colleagues confirmed a reduced penetrance
of 67% of the G2019S mutation in their family-based
sample. Interestingly, the age-dependent penetrance of
the G2019S mutation at age 85 years was nearly doubled
in familial PD compared with randomly ascertained spo-
radic PD patients. Based on the assumption that overesti-
mation of penetrance in these families is unlikely owing
to the given statistical approach, this provides strong sup-
port for the existence of additional genetic or environ-
mental modifiers of penetrance in these families. The
potential impact of these currently unknown modifiers
for disease expressivity culminates in the observed
number of more than 14% phenocopies (relatives with
PD that do not share the LRRK2 mutation) in G2019S-
positive families [11]. This illustrates that these suscepti-
bility factors may confer risk irrespective of G2019S status
and may suffice to cause the PD phenotype in a subset of
family members.
Is there evidence for the presence of additional suscepti-
bility factors in genetically defined PD families? Indeed
the phenomenon of phenocopies has been described in
many of the original multiplex families with established
PD-associated gene mutations, that is, alpha-synuclein and
Parkin [14,15]. These have been typically explained by the
population-based PD prevalence of 200 cases per 100,000
population and regarded as 'independent' [15,16]. How-
ever, the observed role of heterozygous mutations in auto-
somal recessive genes for PD (Parkin, PINK1) as potential
predisposing factors for PD and the substantial propor-
tion of more than 15% phenocopies in a large pedigree
with Parkin-related PD strongly support the idea of an
intrinsic susceptibility profile aggregating in the respective
family background [15,17,18].
What do we already know about implicated genetic sus-
ceptibility factors? As can be deduced from existing stud-
ies, the modifiers of penetrance in LRRK2-related PD are
not related to gender or ethnicity [6,11,19]. Indeed, inde-
pendent genetic modifiers have been identified by large
association studies in sporadic PD and may also modify
penetrance in familial PD. In this context, several studies
on functional polymorphisms in the promoter and 3'-end
region of the alpha-synuclein  gene revealed increased
alpha-synuclein levels associated with an increased risk of
developing PD [20,21]. Thus, polymorphisms in genes
identified in familial PD may exert a disease-modulating
effect that, in concert with other genetic or environmental
susceptibility factors, may drive the accumulated risk over
a critical threshold to cause neurodegeneration.
This may indicate that the same genes that encode fully
penetrant mutations may provide minor alleles that may
contribute to the penetrance-modifying effect leading to
familial clusters of PD (Figure 1). However, recent studies
in patients with co-occurrence of the LRRK2 and Parkin
mutations found no evidence that heterozygous muta-
tions in the Parkin gene, that are suspected to predispose
to PD, modulate the expressivity of LRRK2-related PD
[22,23]. This underscores the need for additional genetic
and epidemiological studies in the genetically defined
subgroup of G2019S-related PD that may help to dissect
hereditary modifiers of penetrance and environmental
factors influencing disease expressivity – the latter
approach being unexpectedly fruitless in the past [24].
Until firm conclusions on the relative penetrance of iden-
tified disease genes like LRRK2 are available, the value of
screening for mutations in asymptomatic family members
of  LRRK2-mutation carriers should be considered with
caution, because until now no neuroprotective therapy
has been implemented and symptomatic treatment is per-
formed regardless of the presence or absence of mutations
in known genes.BMC Medicine 2008, 6:33 http://www.biomedcentral.com/1741-7015/6/33
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